Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on Core & Main, Raises Price Target to $28

RBC Capital analyst Mike Dahl maintains Core & Main (NYSE:CNM) with a Outperform and raises the price target from $27 to $28.
byBenzinga Newsdesk
December 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Mike Dahl maintains Core & Main (NYSE:CNM) with a Outperform and raises the price target from $27 to $28.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Intercept Announces Efficacy And Safety Data From Phase 3 REGENERATE Study In Liver Fibrosis Fue To NASH To Be Presented At NASH-TAG Conference 2023 Jan 6-7

By Benzinga Newsdesk
January 4, 10:08 AM
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.

ICPT